[go: up one dir, main page]

SI3371165T1 - Zaviralec BTK za uporabo pri zdravljenju raka - Google Patents

Zaviralec BTK za uporabo pri zdravljenju raka

Info

Publication number
SI3371165T1
SI3371165T1 SI201631518T SI201631518T SI3371165T1 SI 3371165 T1 SI3371165 T1 SI 3371165T1 SI 201631518 T SI201631518 T SI 201631518T SI 201631518 T SI201631518 T SI 201631518T SI 3371165 T1 SI3371165 T1 SI 3371165T1
Authority
SI
Slovenia
Prior art keywords
treating cancer
btk inhibitor
btk
inhibitor
cancer
Prior art date
Application number
SI201631518T
Other languages
English (en)
Inventor
Bayard R. Huck
Samantha M. GOODSTAL
Claude Gimmi-Mckim
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SI3371165T1 publication Critical patent/SI3371165T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI201631518T 2015-11-04 2016-11-04 Zaviralec BTK za uporabo pri zdravljenju raka SI3371165T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562250575P 2015-11-04 2015-11-04
US201662296143P 2016-02-17 2016-02-17
US201662341189P 2016-05-25 2016-05-25
PCT/US2016/060508 WO2017079542A1 (en) 2015-11-04 2016-11-04 Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity
EP16804956.7A EP3371165B1 (en) 2015-11-04 2016-11-04 A btk inhibitor for use in treating cancer

Publications (1)

Publication Number Publication Date
SI3371165T1 true SI3371165T1 (sl) 2022-05-31

Family

ID=57442803

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631518T SI3371165T1 (sl) 2015-11-04 2016-11-04 Zaviralec BTK za uporabo pri zdravljenju raka

Country Status (22)

Country Link
US (4) US20170119766A1 (sl)
EP (2) EP4014977A1 (sl)
JP (4) JP6913100B2 (sl)
KR (2) KR20250133463A (sl)
AU (4) AU2016349584B9 (sl)
BR (1) BR112018007604B1 (sl)
CA (1) CA3001735A1 (sl)
CY (1) CY1125116T1 (sl)
DK (1) DK3371165T3 (sl)
ES (1) ES2912059T3 (sl)
HU (1) HUE058323T2 (sl)
IL (2) IL293093B2 (sl)
LT (1) LT3371165T (sl)
MX (2) MX388890B (sl)
NZ (1) NZ741293A (sl)
PL (1) PL3371165T3 (sl)
RS (1) RS63146B1 (sl)
RU (2) RU2022100782A (sl)
SG (2) SG11201802927VA (sl)
SI (1) SI3371165T1 (sl)
TW (3) TW202510883A (sl)
WO (1) WO2017079542A1 (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202510883A (zh) * 2015-11-04 2025-03-16 德商默克專利有限公司 使用具有ｂｔｋ抑制活性之嘧啶及吡啶化合物治療癌症之方法
EP3377484B1 (en) * 2015-11-17 2023-09-06 Merck Patent GmbH Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
US11186554B2 (en) * 2017-05-03 2021-11-30 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
KR20210022674A (ko) * 2018-06-19 2021-03-03 메르크 파텐트 게엠베하 1-(4-｛[6-아미노-5-(4-페녹시-페닐)-피리미딘-4-일아미노]-메틸｝-4-플루오로-피페리딘-1-일)-프로펜온의 신규한 결정 형태, 이의 염 형태, 및 이를 수득하는 방법
JP7555327B2 (ja) 2018-07-25 2024-09-24 ノバルティス アーゲー Ｎｌｒｐ３インフラマソーム阻害剤
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US20240024314A1 (en) * 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
EP4196478A1 (en) 2020-08-14 2023-06-21 Novartis AG Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
US11866421B2 (en) 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
US20250064805A1 (en) * 2022-01-14 2025-02-27 Telios Pharma Inc. Methods of Treating Myeloproliferative Disorders Based on BTK Occupancy & Resynthesis Rate
EP4543452A1 (en) 2022-06-24 2025-04-30 Merck Patent GmbH Treatment regimen for autoimmune diseases and inflammatory diseases
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19649896A1 (de) * 1996-12-02 1998-06-04 Henkel Kgaa Geformte Seifenprodukte
AR038955A1 (es) * 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
DE602005027825D1 (de) * 2004-03-30 2011-06-16 Vertex Pharma Als inhibitoren von jak und anderen proteinkinasen geeignete azaindole
JP2011500823A (ja) * 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
AR071717A1 (es) * 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
LT2718270T (lt) * 2011-06-10 2022-08-10 Merck Patent Gmbh Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai
TW201414734A (zh) * 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
WO2014093230A2 (en) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
WO2014151620A1 (en) 2013-03-14 2014-09-25 Boehringer Ingelheim International Gmbh 5-thiazolecarboxamide dervatives and their use as btk inhibitors
WO2015042078A2 (en) * 2013-09-22 2015-03-26 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
GB201404987D0 (en) * 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
TW202510883A (zh) * 2015-11-04 2025-03-16 德商默克專利有限公司 使用具有ｂｔｋ抑制活性之嘧啶及吡啶化合物治療癌症之方法
EP3377484B1 (en) * 2015-11-17 2023-09-06 Merck Patent GmbH Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity

Also Published As

Publication number Publication date
AU2016349584A1 (en) 2018-04-26
JP7295169B2 (ja) 2023-06-20
MX2018005461A (es) 2018-08-01
JP6913100B2 (ja) 2021-08-04
US20170119766A1 (en) 2017-05-04
IL293093B2 (en) 2024-07-01
AU2023203377A1 (en) 2023-06-29
IL258979A (en) 2018-06-28
RS63146B1 (sr) 2022-05-31
IL293093A (en) 2022-07-01
MX2021015826A (es) 2022-02-03
TWI858413B (zh) 2024-10-11
CY1125116T1 (el) 2024-12-13
RU2018120153A (ru) 2019-12-05
HUE058323T2 (hu) 2022-07-28
IL293093B1 (en) 2024-03-01
WO2017079542A1 (en) 2017-05-11
IL258979B (en) 2022-06-01
JP2023105214A (ja) 2023-07-28
KR20250133463A (ko) 2025-09-05
KR102850604B1 (ko) 2025-08-27
PL3371165T3 (pl) 2022-05-02
TW201722430A (zh) 2017-07-01
DK3371165T3 (da) 2022-05-02
ES2912059T3 (es) 2022-05-24
LT3371165T (lt) 2022-05-10
TW202510883A (zh) 2025-03-16
RU2022100782A (ru) 2022-02-03
US20250161304A1 (en) 2025-05-22
US20200206224A1 (en) 2020-07-02
AU2021211982B2 (en) 2023-03-02
BR112018007604B1 (pt) 2022-08-16
TWI783915B (zh) 2022-11-21
EP3371165A1 (en) 2018-09-12
RU2765154C2 (ru) 2022-01-26
MX388890B (es) 2025-03-20
JP2025023232A (ja) 2025-02-14
CA3001735A1 (en) 2017-05-11
AU2025204315A1 (en) 2025-06-26
BR112018007604A2 (pt) 2018-10-23
SG11201802927VA (en) 2018-05-30
JP2021165308A (ja) 2021-10-14
NZ741293A (en) 2023-06-30
EP3371165B1 (en) 2022-01-26
SG10202005292UA (en) 2020-07-29
KR20180073599A (ko) 2018-07-02
RU2018120153A3 (sl) 2020-03-05
JP2018532805A (ja) 2018-11-08
AU2016349584B9 (en) 2021-06-03
US20210244736A1 (en) 2021-08-12
CN108779095A (zh) 2018-11-09
AU2016349584B2 (en) 2021-05-13
EP4014977A1 (en) 2022-06-22
US11491153B2 (en) 2022-11-08
TW202320784A (zh) 2023-06-01
AU2021211982A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
IL323396A (en) Cancer treatment methods
IL289947A (en) A method for treating cancer
PL3371165T3 (pl) Inhibitor btk do zastosowania w terapii rakowej
IL272724B (en) Gemcitabine drug inhibitors
SG10202005298RA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
PT3500299T (pt) Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
SG11201705810YA (en) Device for treating a surface
IL251630A0 (en) Combined therapy for use in cancer treatment
IL249231A0 (en) Pharmaceutical combinations for cancer treatment
IL256836B (en) Methods for treating cancer using apilimod
PT3164394T (pt) Inibidores gls1 para o tratamento de doenças
SMT202100207T1 (it) Inibitori della farnesiltransferasi per il trattamento del cancro
PL4008329T3 (pl) Związki izoksazoliny do zastosowania w leczeniu demodekozy
LT3463436T (lt) Vakcina derinyje su imuninės patikros taško slopikliu, skirta vėžiui gydyti
EP3736275C0 (en) PRODRUGS OF OXABICYCLOHEPTANE FOR USE IN THE TREATMENT OF CANCER
SG11201709818WA (en) Device for treating a surface
IL255023A0 (en) Methods of treating cancer with stat3 pathway inhibitor and kinase inhibitor
PL3518911T3 (pl) Rad1901 do zastosowania w leczeniu nowotworu jajnika
HK1262072A1 (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
AP2016009066A0 (en) A drug for treating cancer
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201414904D0 (en) Materials and methods for treating cancer